Classifying these additional patients under ICBD facilitated the initiation of approved biologic treatments (e.g., monoclonal anti-TNF), potentially improving the management of BD, particularly in patients with ocular involvement and without oral ulcers. This evidence concerns the gene TNF and Behcet disease.